Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
15.36 USD +2.74% Intraday chart for Biomea Fusion, Inc. -2.66% +5.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Tech in Focus on -2- DJ
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function CI
Truist Securities Starts Biomea Fusion With Buy Rating, $55 Price Target MT
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219 CI
Biomea Fusion, Inc. Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts CI
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes CI
Biomea Fusion Says Long-Term Data Show Improved Glycemic Control in Phase 2 Trial of BMF-219 to Treat Diabetes MT
Biomea Fusion's Ongoing Phase 2 Study of BMF-219 Shows Glycated Hemoglobin Reductions in Patients With Type 2 Diabetes MT
Biomea Fusion Receives Health Canada Clearance for Phase 2 Trial of BMF-219 in Type 1 Diabetes MT
Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application for BMF-219 in Type 1 Diabetes CI
Biomea Fusion Surges Nearly 20% Premarket Wednesday MT
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease CI
Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023 CI
Biomea Fusion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103) CI
Biomea Fusion Investigational New Drug Application for Diabetes Candidate Approved by FDA MT
Biomea Fusion Gets FDA, Health Canada Clearance for Expansion Groups in Mid-Stage Diabetes Study MT
Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study CI
Biomea Fusion Names Juan Pablo Frias as Chief Medical Officer, Steve Morris to Become Chief Development Officer MT
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer CI
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Scotiabank Starts Biomea Fusion at Sector Outperform With $41 Price Target MT
Biomea Fusion's Ongoing Phase 1 Trial of BMF-219 Shows Complete Responses in Two Acute Myeloid Leukemia Patients MT
Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations CI
North American Morning Briefing : Stock Futures -2- DJ
Chart Biomea Fusion, Inc.
More charts
Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The Company has built FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical covalent programs for the treatment of select cancers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.36 USD
Average target price
54 USD
Spread / Average Target
+251.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Biomea Fusion, Inc. - Nasdaq
  4. News Biomea Fusion, Inc.
  5. Biomea Fusion : Piper Sandler Starts Biomea Fusion at Overweight With $27 Price Target